Appendix Cancer & PMP Treatment in Hyderabad

Overview

Understanding Appendix Cancer & PMP

Appendiceal tumours are rare but important — they range from benign mucinous cystadenoma to malignant appendiceal adenocarcinoma and goblet cell adenocarcinoma. The most clinically significant is pseudomyxoma peritonei (PMP): a condition caused by a perforated appendiceal mucinous tumour that seeds the peritoneal cavity with mucin-producing cells, gradually filling the abdomen with gelatinous material.

PMP is unique among peritoneal malignancies in that it is predominantly a local disease — it spreads along the peritoneal surfaces without typically invading organs or metastasising to distant sites. This makes it uniquely amenable to complete cytoreductive surgery (CRS) combined with HIPEC, with long-term survival and potential cure possible even in advanced cases. 10-year survival rates exceed 80% in low-grade PMP treated at specialist centres.

The critical challenge is that PMP is frequently misdiagnosed — patients undergo multiple laparotomies for “ovarian cysts”, “bowel obstruction”, or “appendicitis” before the correct diagnosis is made. Each unnecessary surgery creates adhesions and disseminates mucin, making subsequent CRS harder. Any patient with a mucocele of the appendix, “jelly belly” appearance, or unexplained mucinous ascites should be referred to a specialist before any operation.

At a Glance

Most common type: Low-grade appendiceal mucinous neoplasm (LAMN) → PMP
Disease spread: Peritoneal surfaces — does not typically metastasise to liver/lungs
Curative treatment: CRS + HIPEC — the Sugarbaker technique
Prognosis (low-grade): >80% 5-year, >60% 10-year survival
Prognosis (high-grade/goblet cell): 40–60% 5-year survival with complete CRS+HIPEC

Warning Signs

Recognising Appendix Cancer & PMP

PMP often presents late with vague symptoms — the classic “jelly belly” presentation is a late finding. Any of these should prompt specialist evaluation.

🤰
“Jelly Belly” Distension

Progressive abdominal distension with a characteristic jelly-like consistency due to mucinous ascites.

😣
Abdominal Pain / Mass

Right iliac fossa pain or mass — often initially attributed to appendicitis or ovarian cyst.

🚽
Bowel Habit Changes

Constipation or obstruction as mucin deposits compress the bowel.

🤢
Nausea & Vomiting

Progressive nausea from bowel compression or obstruction by mucin.

🩺
Incidental CT Finding

Mucocele of the appendix found on CT done for another reason — requires specialist referral before any intervention.

⚕️
Previous Ovarian Cyst Surgery

Women with recurrent “ovarian cysts” or mucinous ovarian masses — consider appendiceal primary.

Our Approach

Surgical Treatment of PMP and Appendix Cancer

The treatment of PMP and appendiceal adenocarcinoma is CRS + HIPEC — the “Sugarbaker procedure”, developed by Dr. Paul Sugarbaker, who pioneered peritoneal surface oncology. I trained in this technique at Medizinische Hochschule Hannover and have performed this operation for Indian patients who previously had to travel abroad.

CRS involves a systematic removal of all peritoneal surfaces bearing mucin or tumour deposits — peritonectomy of the right and left abdominal wall, right and left diaphragm, pelvic peritoneum, omentectomy, and any involved organ segments. The goal is complete cytoreduction (CC0 — no visible residual disease). HIPEC with mitomycin C or oxaliplatin is then administered.

The key message for PMP is: do not operate before consulting a specialist. Incomplete surgery — removing some mucin and closing — is worse than no surgery. It creates adhesions, disseminates disease, and makes the definitive CRS+HIPEC technically harder. Refer to a specialist centre for initial management planning.

Surgical Procedure
CRS + HIPEC (Sugarbaker Technique)

Complete removal of peritoneal disease followed by heated intraperitoneal chemotherapy — curative intent for PMP.

Learn more →

Surgical Procedure
Appendix Cancer & PMP Surgery

Specialist appendiceal tumour resection and PMP management.

Learn more →

Why Choose Us

Expertise You Can Trust

Dr. Mohammed Imaduddin brings internationally trained surgical skills and a patient-first philosophy to every case.

500+
Complex Oncological Surgeries Performed
15+
Years in Surgical Oncology
3
International Training Centres (Hannover, Charité, AIIMS)
FACS
Fellow of the American College of Surgeons

Common Questions

Frequently Asked Questions

The most important questions from patients and families dealing with PMP and appendix cancer.

Can PMP be cured?
Yes — PMP is one of the most curable forms of peritoneal malignancy. For low-grade LAMN-associated PMP, 10-year survival rates exceed 80% and long-term disease-free survival is achievable. Even high-grade and goblet cell appendiceal carcinoma with peritoneal spread has 5-year survival rates of 40–60% with complete CRS+HIPEC. The prognosis is closely tied to completeness of resection — CC0 is the goal.
My CT shows a mucocele of the appendix — should I have surgery immediately?
Not immediately, and not at any surgeon — you should be referred to a specialist in peritoneal oncology first. The mucocele must be carefully staged (CT abdomen/pelvis with contrast), and the operation must be planned to avoid spillage of mucin-producing cells. An inadvertently ruptured mucocele in an unplanned laparoscopic appendectomy can seed the peritoneum and convert a simple problem into widespread PMP. Please seek specialist evaluation before any operation.
How long is recovery from CRS + HIPEC for PMP?
CRS + HIPEC for PMP is a major operation — often lasting 8–12 hours for extensive disease. Hospital stay is typically 10–14 days. Most patients return to normal activity over 6–8 weeks. The recovery is significant but patients consistently report it is worthwhile — particularly given the curative potential of the procedure. Long-term quality of life after successful CRS + HIPEC for PMP is generally excellent.
What is goblet cell adenocarcinoma of the appendix?
Goblet cell carcinoma (GCC) is a mixed exocrine-neuroendocrine tumour of the appendix with more aggressive behaviour than low-grade mucinous neoplasms. It has a higher propensity for peritoneal and systemic spread, and a lower chance of cure with CRS+HIPEC compared to low-grade PMP. However, surgery remains the cornerstone — adjuvant chemotherapy with FOLFOX or capecitabine/oxaliplatin is recommended for all stages.
Can PIPAC help if I am not eligible for CRS + HIPEC?
Yes — for patients who cannot undergo open CRS+HIPEC (due to extensive disease, multiple prior surgeries, or poor fitness), PIPAC offers a minimally invasive alternative. It delivers chemotherapy (mitomycin C and cisplatin) as a pressurised aerosol directly into the peritoneal cavity under laparoscopic vision, repeated every 6 weeks. In high-grade disease or as a “bridge” to make patients eligible for definitive surgery, PIPAC has demonstrated meaningful tumour response rates.

Ready to Discuss Your Case?

Every cancer journey is different. I offer a detailed, unhurried consultation to help you understand your options and make informed decisions.